Featured
Pharma bosses call out work-life balance
Two senior pharma executives - one a former Aussie GM - have called out perfect work-life balance as an unrealistic expectation placed on the industry
Regulatory & Reimbursement
This drug won a standing ovation but will Aussies ever see it?
A breakthrough drug for pancreatic cancer was given a standing ovation at ASCO this year but for Australian patients there's likely a long wait ahead
Regulatory & Reimbursement
Double or nothing: Unlocking access to new drugs
Medicines Australia has outlined an ambitious plan for the Government to double its spending on innovative medicines
Jobs & Workplace
Sydney exec lands GM role overseas
Stepping up from a Business Unit Director role, this executive has packed her bags and made the move to Bulgaria, to take on the position of General Manager at a Big Pharma
Industry & Companies
ACCC approves $68 billion acquisition
The ACCC has given the go-ahead for the merger of a Johnson & Johnson spin-out with another mega company... but on one condition
Regulatory & Reimbursement
Another domino falls for drug in TGA probe
With another jurisdiction revoking approval, it's not looking good for a drug that has been linked to eight deaths overseas that is being reviewed by the TGA.
Regulatory & Reimbursement
BMS notches a first with TGA tick
Once-daily pill, the first treatment of its kind to be registered in Australia for a debilitating condition, marks an 'important milestone' for patients
Industry & Companies
Pharma rejoins Medicines Australia
Several years after leaving the industry body, this company has returned as a Class 1 member, saying the innovative medicines sector is strongest when it works together
Featured
Does Aussie pharma pass the Pub Test?
Companies have been urged to apply the "PUB Test" to upcoming initiatives designed to engage HCPs - before they go to market - otherwise they risk missing the mark
Jobs & Workplace
Big Pharma picks Sydney CBD for new HQ
General Manager announces a “fresh start” for the pharma in a slick new office space with the latest technology and design to enable flexible-based working plus connection with patients and partners
Regulatory & Reimbursement
The secrecy that hampers PBAC decisions
There can be clear disagreements over the price which should be paid for a drug, but some features of the reimbursement system mean neither side really knows what the other expects
Industry & Companies
What's the ROI of government mRNA initiatives?
Millions of dollars have been spent by the Victorian Government to nurture the mRNA industry in the state, and a new Impact Report details whether it's delivered
Industry & Companies
Who has the most effective MSLs, and why?
A survey of US oncologists has revealed what separates highly effective MSL teams from average ones and without prompting, doctors named the companies that stand out
Jobs
Regulatory & Reimbursement
September PBS listings climb to eight
Six pharmas have expanded their drugs on the PBS this month - including the first biologic added to the scheme for adults with uncontrolled COPD - with two companies scoring a double win
Regulatory & Reimbursement
CSL lowers prices in Trump MFN deal
CSL and eight other pharmas have signed a Most Favoured Nation deal with the US, with the Aussie giant saying it does not anticipate any 'material impact' during fiscal year 2027
Industry & Companies
Pharma deal to ramp up retail reach in Australia
New commercial collaboration bringing together 'complementary strengths' of two pharmas is a stepping-stone to further collaboration across a broad pipeline
Featured
Who’s up for a 2026 PRIME Award?
The 22nd PRIME Awards have attracted entries from more organisations than ever before making this one of the strongest and most competitive fields in the event's history
Regulatory & Reimbursement
CEO raises red flag on PBS transparency
Boss warns there is currently no mechanism to disclose a drug’s commercial history citing the example of a treatment originally developed by Big Tobacco
Industry & Companies
$10M for Aussie infectious diseases innovation
Six Australian companies addressing significant local and global unmet health needs in infectious diseases are getting support to break into commercial success
Regulatory & Reimbursement
World's biggest drug wins broad PBS listing
After a gruelling decade-long battle, a milestone PBS listing will see this oncology blockbuster made available to thousands of Australians living with certain advanced and metastatic cancers, including rare cancers
Regulatory & Reimbursement
Company scores double PBS win
It's been quite the week for this company which announced a new General Manager on Friday and from tomorrow, two of its biggest drugs will be expanded
Latest
Spring blooms with fresh PBS listing
First-of-its-kind treatment in an area of unmet need scores a Spring PBS listing with the company's GM underlining the importance of innovative medicines for economic growth
Regulatory & Reimbursement
TGA reins in breast cancer label
Australia's regulator has narrowed the patient population eligible for a breast cancer drug, after initially granting approval for a broader population than other major jurisdictions
- Leadership & People ANZ GM lifts the lid on best workplace culture
- Industry & Companies Global boss: Why strong science isn't enough
- Industry & Companies King Kong of drugs a revenue booster
- Regulatory & Reimbursement Single-pill triple therapy wins TGA tick
- Other News Aussie patients name industry's best
- Regulation & Legal Double recognition for Aussie IP strategist
- Industry & Companies Who's been crowned an Aussie Best Workplace?
- Leadership & People Company names new Aussie Country Leader
- Industry & Companies Patients choosing between meds or meals
- Regulatory & Reimbursement Who's at the PBAC's next meeting?
